Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins

Keyphrases

• Pharmacokinetics-pharmacodynamics (PK-PD) 100%
• Triazole 100%
• Echinocandins 100%
• Pharmacodynamic Research 100%
• Pharmacodynamic Study 30%
• Pharmacodynamic Target 30%
• Clinical Pharmacology 23%
• Antifungal Drugs 23%
• Human Studies 15%
• Therapeutic Drug Monitoring 15%
• Invasive Candidiasis 15%
• Dose Optimization 15%
• Fluconazole 15%
• Rezafungin 15%
• Novel Antifungals 15%
• Fungi 7%
• Clinical Outcomes 7%
• Posaconazole 7%
• Changing Epidemiology 7%
• Patient Demographics 7%
• Voriconazole 7%
• Invasive Aspergillosis 7%
• Drug Dosing 7%
• Treatment Decisions 7%
• Reduced Susceptibility 7%
• Isavuconazole 7%
• Candida Species 7%
• Clinical Model 7%
• Comparative Effectiveness 7%
• Itraconazole 7%
• Altered Pharmacokinetics 7%
• Current Therapeutics 7%
• Emerging Infections 7%
• Invasive Fungal Infection 7%
• Azole Antifungals 7%
• Special Patient Population 7%
• Rare Fungal Infections 7%
• Pharmacodynamics Target Attainment 7%
• Selection Optimization 7%
• Coccidioides Spp 7%
• Dosing Recommendations 7%
• Augmented Renal Clearance 7%
• Infection Infection 7%
• Randomized Comparative Study 7%
• Candida Auris 7%
• Aurès 7%
• Emerging Pathogen 7%
• Azole-resistant Aspergillus Fumigatus 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacodynamics 100%
• Triazole Derivative 100%
• Pharmacokinetics 100%
• Echinocandin 100%
• Antifungal Agent 46%
• Clinical Pharmacokinetics 23%
• Infection 23%
• Human Study 15%
• Therapeutic Drug Monitoring 15%
• Invasive Candidiasis 15%
• Fluconazole 15%
• Rezafungin 15%
• Pyrrole 15%
• Posaconazole 7%
• Invasive Aspergillosis 7%
• Voriconazole 7%
• Infectious Agent 7%
• Mycosis 7%
• Candida 7%
• Isavuconazole 7%
• Itraconazole 7%
• Systemic Mycosis 7%
• Candida Auris 7%
• Aspergillus fumigatus 7%
• Coccidioides 7%
• Triazole 7%